

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/01, 15/87, 15/64, C07K 14/005, 16/00		A1	(11) International Publication Number: WO 95/16027
			(43) International Publication Date: 15 June 1995 (15.06.95)
(21) International Application Number: PCT/SE94/01166		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 5 December 1994 (05.12.94)			
(30) Priority Data: 9304060-8 6 December 1993 (06.12.93) SE			
(71) Applicant (for all designated States except US): BIOINVENT INTERNATIONAL AB [SE/SE]; Sölvegatan 41, S-223 70 Lund (SE).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BORREBAECK, Carl, A., K. [SE/SE]; Åttevägen 8 A, S-245 62 Hjärup (SE). DUENAS, Marta [CU/CU]; Pasaje Gral Lee #19, entre 10 de Octubre y Rabi, Stos Suares, 10 de Octubre, Ciudad Habana (CU).			
(74) Agent: AWAPATENT AB; P.O. Box 5117, S-200 71 Malmö (SE).			

(54) Title: METHOD OF SELECTING SPECIFIC BACTERIOPHAGES

(57) Abstract

A method for selecting a molecule, such as an antibody, antigen, peptide, protein or fragment thereof, which molecule is expressed together with a phage coat protein on the phage's surface. The method is characterised by linking phage replication to recognition of the molecule on the surface of the phage. The linkage can be achieved by use of a fusion protein between phage protein 3 and a specific binding ligand for the molecule.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Method of selecting specific bacteriophages
Technical Area of the Invention

The present invention concerns a method for selecting a molecule, such as an antibody, antigen, peptide, protein or fragment thereof, which molecule is expressed together with a phage coat protein on the phage's surface.

Background of the Invention

Monoclonal antibodies were introduced in 1975 by George Köhler and Cesar Milstein. The concept comprises fusing immune B lymphocytes from mice with a tumour cell line, for instance a myeloma/plasmacytoma. The resulting hybrid myeloma (= hybridoma) will possess the following two distinct properties: 1. produce specific antibodies; and 2. live infinitely in cell culture. The first of these properties is inherited from the immune mouse cells, whereas the second one comes from the tumour cell line. The hybridoma prepared as outlined above, will produce so-called monoclonal antibodies of high specificity and in infinite amounts; properties which makes them especially suitable for use in biomedical applications.

Human therapy using monoclonal antibodies does however require human antibodies, among other because an unwanted glycosylation appears on the mouse antibodies, which renders these antibodies directly unsuitable for human therapy (Borrebaeck et al., 1993). Human monoclonal antibodies have however shown themselves to be considerably much harder to produce than the mouse antibodies, especially because human beings can not be immunised due to ethical considerations. This means that the starting material, i.e. the immune B lymphocytes, has not been optimal. The main problem has been that the number of immune B lymphocytes has been very low in non-immunised individuals, which makes it extremely difficult to select specific antibodies from said B lymphocytes.

In 1985 Smith (Smith, 1985) published a method which dramatically changed how antibodies and especially human antibodies could be produced. Smith showed how small peptides could be expressed together with a phage coat protein on a filamentous phage (virus which infects bacteria). As filamentous phages allow even foreign proteins to be expressed on some of their own coat proteins, such as for instance protein 3 or protein 8, these phages are very well suited for expression of even the relatively big antibody fragments, such as for instance Fab or Fv (McCaffery et al., 1990; Barbas et al., 1991; Huse 1991).

The method for placing the antibody fragment on the phage surface is the following:
From a starting material which comprises B lymphocytes, such as blood, lymphoid tissue or the like, the B lymphocytes are separated and a gene library of the antibodies produced by said B lymphocytes is erected. The genes encoding the variable heavy and light antibody

domains (V_H and V_L) are amplified through the so-called PCR-method (PCR=Polymerase Chain Reaction), which was first described applied on antibodies by Larrick et al. (1989). These amplified gene segments, which codes for all different antibody specificities found in the starting material used, are thereafter cloned into a so-called phagemid vector with a random combination of different V_H/V_L genes (Huse et al., 1989). The result of this cloning is that all available specificities can be immortalised in one single step and in a following step they may be expressed on the surface of a filamentous phage together with for example coat protein 3. Those phages which express an antibody fragment with the sought after specificity can then be selected by taking advantage of the surface displayed antigen receptor, i.e. the antibody fragment. In summary, it can be said that all antibody specificities in a certain starting material can be directly immortalised by PCR amplification and thereafter expressed on the surface of a phage.

Theoretically this method gives access to the complete pool of antibodies found in the immune system. This pool consists of up to 10^{14} different antibody specificities and at a given point of time in a human beings life approximately 10^8 - 10^9 different specificities will be available. The selection of one (1) antibody specificity out of the pool of for instance 10^9 is a very difficult task, in many cases impossible if there are not more than one or a few copies of the wanted specificity.

Different modes of selection have been published, all of which depend on for instance conventional affinity chromatography of the phages or simply a panning procedure where the phages are bound to an antigen covered plastic surface from which the specifically bound phages, i.e. those containing a specific antibody fragment can be isolated. Antigen specific panning and affinity chromatography will in the best of cases only reward a purification factor of 1000 times, and in many cases only a factor of 50-100 times per step.

Definition of the Invention

It has now been found that a surprisingly much simpler and more efficient selection of the phages expressing antibodies or antibody fragments of wanted specificity on their surface can be achieved by linking specific phage replication to the antigen recognition of said antibodies or antibody fragments on the phage's surface.

Further, the selection according to this invention, although especially suitable for selecting human antibodies, may be used for the selection of any molecule, which may be expressed on the surface of a phage together with phage coat protein 3.

Examples of such molecules are peptides, proteins, antigens, antibodies and fragments thereof, and in this specification and the claims, the term "ligand I" will be used to denominate said molecules.

Further, the term "ligand II" will, in this specification and the claims, be used to denominate any group or molecule, which can interact specifically, i.e. bind or be bound by said ligand I on the surface of a phage. Examples of groups or molecules which may act as ligand II are peptides, proteins or fragments thereof, organic molecules, hormones or fragments thereof.

Detailed description of the invention

The aim of the method according to the present invention is to make available an efficient method of selection based on that specific recognition of a phage, through a ligand I on its surface leads to an ability to replicate and multiply.

The present invention links recognition of a ligand carried on the phage and the phage's replication. This is a direct mimicry of the humoral immune system theory of clone selection where only antigen specific B lymphocytes proliferate and differentiate in an antigen driven process. Since ligand recognition is linked to phage replication this means that only the specific phages replicate, i.e. multiply and this makes possible an easy selection of the phage carrying a ligand even if this phage is surrounded by hundred thousands of non-specific phages.

The method according to the present invention which comprises linking specific phage replication and recognition of a ligand I on the phage surface, is achieved by

- a.) letting a helper phage stock, which phages do not have gene3 but carry protein3 in their coats, infect bacteria which carry a phagemid vector with a cloned ligand I;
- b.) add a fusion protein comprising protein3 or a part thereof, and a ligand II specifically interacting with said ligand I, so that ligand I and ligand II bind specifically to each other;
- c.) let said specific phages, which carry ligand I, ligand II and protein3 on their surface infect bacteria and thereby replicate and multiply.

Any filamentous phage may be used as helper phage by removal of gene3, because this renders the phage non-infectious since protein3, expressed by gene3, is the protein which binds to the pili of the bacterium and thereby mediates an infection of bacteria by phages. Examples of filamentous phages, which may be transformed into helper phages usable in this invention are M13, fd and fl. It is preferred to use a M13 helper phage, which after the removal of gene3 has been named M13 MDΔ3.

The fusion protein may be a true fusion protein or a similarly linked molecule making available a combination of protein3 and a ligand II. In this specification and the claims, the term "fusion protein" is used in the meaning to encompass both genetically produced fusion proteins and chemically linked molecules of protein3 and ligand II, and further, the term "fusion protein" is also ment to encompass molecular structures constructed with a receptor-ligand pair between protein3 and ligand II. An example of such a receptor-ligand pair is biotin-avidin, but other such receptor-ligand pairs are well-known in the art. Thus, the "fusion protein" may be any combination linking protein3 and ligand II, directly or indirectly.

The ligand II in the fusion protein, for instance an antigen, will interact specifically with those phages having a specific ligand I, an antibody or antibody fragment, on their surface and these phages can now infect bacteria, such as E. coli, as ligand II is linked to protein3, which mediates infection. Thereby, replication and multiplication can occur and the ligand recognition is linked to specific phage replication. All other phages which are non-specific for the ligand II in the fusion protein do not receive the ability to infect are left behind as a background during the selection process.

In order to produce a helper phage stock of a truncated infectious phage, such as for instance M13MDΔ3, this is transfected into bacteria, such as E. coli, which already contain gene3 on a plasmid, for example a pUC19 plasmid. The resulting extruded phage, will not contain gene3 but protein3 and can thus only infect bacteria, such as E. coli once. The thus produced helper phage stock is now used to infect E. coli containing phagemid vectors with cloned regions from different ligands, for example antibodies. The result will be a new phage stock where the phages express a ligand I on their surface linked to a truncated protein3 from the phagemid vector. These phages cannot infect again and thus they can not replicate and multiply.

Apart from the plasmid pUC19, any other bacterial expression vector may be used for cloning gene3 into the bacteria.

The method according to the invention, linking replication of a phage to specific recognition, allows for the first time the use of starting materials for generation of antibodies, which includes only very few copies, because it makes possible the amplification of the specific phage many million times. In this manner a method is created which gives access to the wanted antibody specificities after the same principle which the body uses for selecting its antibody specific B cells.

It is especially preferred to use the process according to the present invention for selection of human antibodies, by using said human antibody as ligand I.

Description of the Figures

Figure 1 gives a description of the principle for linking ligand recognition to phage replication by selection of specific phages according to the present invention (* M13 MDdelta3 is a helper phage lacking gene 3, i.e. not itself infectious).

Figure 2 shows the result of an experiment where the specificity and selectivity of the selection process is demonstrated.

Working Examples

Preparation of helper phage stock, M13MD Δ 3

The construction of a mutant phage M13MD Δ 3 (devoid of gene 3) was performed by digestion of the replicative form (RF) DNA of M13KO7 (Viera, J. and Messing, J. 1987) with BspHI and XmnI removing the fragment between residue 1299 and 2646 (according to the numbering of Wezenbeek et al. (Wezenbeek, P. M. G. F., Huselbos, T. J. M. and Schoenmakers, G. G. 1980) In order to reincorporate a fragment from residue 1299 to 1525 containing gene VIII and part of gene IX, this sequence was PCR amplified from M13 KO7 template using the primers 1299(BspHI): 5'-ACTTCCTCATGAAAAAGTC-3' and 1525(XmnI): 5'-GGGAAATTATTCTTATCAGCTTGC-3'. Following digestion, the PCR fragment was cloned in the 7.3 kb RF DNA originating from M13KO7. Helper phage stocks were prepared as described (Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P. and Winter, G. 1991), except for the use of TG1 transformed with pUC19 vector, containing gene 3 that produced an intact protein 3 from M13. The result phage thus had the same proteins as the wild type but did not contain gene 3. This phage was able to infect a male host cell once but any subsequently extruded particles were non-infectious.

Example 1

Three different phage stocks, where each stock contain phages which express antibody fragments specific for respectively hen egg lysozyme (HEL), phenyloxazon (phox) or gp120 on the human immunodeficiency virus (LTC), were prepared separately. The three different phagemids are transfected into XL1 Blue bacteria and are cultivated with ampicillin selection. Thereafter these bacteria are infected with a helper phage, M13MD Δ 3, which does not itself contain gene3, thereby producing non-infectious phage stocks since protein 3 which mediates infection is not included. The three different phage are prepared by centrifugation and filtration and are mixed with different amounts of a fusion protein between a truncated protein3 (only the 98 N-terminal amino acids) and HEL (dp3-HEL), whereupon it is incubated over night. The following day XL1 Blue bacteria are infected with these three phage stocks and Figure 2 shows that only the phages carrying the correct receptor on their surface, i.e. the antibody fragment specific for HEL has been given the ability to replicate and multiply. The linking between ligand recognition and replication has increased the specific phage titre from a background level of 10^2 up to more than 10^8 cfu/ml, which is a specific increase of more than a million times. Further, (as appears from the figure 2), the non specific phages did not replicate at all, but stayed on the background titre of 10^2 cfu/ml.

Example 2

Three different phagemids, which express antibody fragments specific for hen egg lysozyme (HEL) or phenyloxazon (phox) or gp120 on the human immunodeficiency virus (LTC), were mixed in the relation 1:1500:1500. This mixture were transfected into XL1 Blue bacteria and are cultivated with ampicillin selection. Thereafter these bacteria are infected with a helper phage, M13MD Δ 3, which does not itself contain gene3, thereby producing non-infectious phages. The phages are prepared by centrifugation and filtration and are mixed with 30 weight % of a fusion protein of a truncated protein3 (only the 98 N-terminal amino acids) and HEL (dp3-HEL), which is incubated over night. The following day XL1 Blue indicator bacteria are infected with this phage stock and are cultivated over night with ampicillin selection. A little more than one hundred colonies are selected and are cultivated further in a 96 hole cultivating plate where they are infected by the wild type of the helper phage M13 KO7, which carries the gene3. This results in the production of phages from every colony, which can be detected using a phage-ELISA. Table 1 shows that the concentration factor in the first antigen specific step is $>10^5$ times and approximately 10^{10} times after the second selection step. This happens because the fusion protein (dp3-HEL) links antigen recognition with specific replication of HEL specific phages, i.e. phages expressing the antibody fragment specific against HEL on their surface.

References

- Barbas, C. F., Kang, A. S., Lerner, R. A. & Benkovic, S. J. *Proc. Natl. Acad. Sci. (USA)* 88, 7978 (1991).
- Borrebaeck, C. A. K., Malmborg, A. & Ohlin, M. *Immunol. Today* 14, 477 (1993).
- Huse, W. D., Sastry, L., Iverson, S. A., Kang, S. A., Alting, M. M., Burton, D. R., Benkovic, S. J. & Lerner, R. A. *Science* 246, 1275 (1989).
- Huse, W. D. In *Antibody Engineering: A Practical Approach* (Borrebaeck, C. A. K., ed.) p. 103, W. H. Freeman and Co., New York (1991).
- Larrick, J. W., Danielsson, L., Brenner, C. A., Abrahamsson, M., Fry, K. E. & Borrebaeck, C. A. K. *Biochem. Biophys. Res. Commun.* 160,1250 (1989).
- McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. *Nature* 348, 552 (1990).
- Smith, G.P. *Science* 228, 1315 (1985).
- Viera, J. and Messing, J. 1987. Production of single strand plasmid DNA. 1987. *Meth. Enzymol.* 153:3-11
- Wezenbeek, P. M. G. F., Huselbos, T. J. M. and Schoenmakers, G. G. 1980. Nucleotide sequence of filamentous bacteriophage M13 DNA genome: comparison with phage fd. *Gene* 11:129-148.
- Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P. and Winter, G. 1991. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. *Nucleic Acid. Res.* 19:4133-4137.

Table 1

Clonal mixture	Initial ratio	Final ratio	Enrichment factor
First round of enrichment			
pEXmide HEL/ pEXmide Phox + pEXmide LTC	$1/3 \times 10^4$	82/20	1.2×10^5
	$1/3 \times 10^5$	49/59	2.5×10^5
	$1/3 \times 10^6$	4/104	1.1×10^5
	$1/3 \times 10^7$	0/108	-
Second round of enrichment			
	$1/3 \times 10^8$	103/5	6.1×10^9
	$1/3 \times 10^9$	55/53	3.1×10^9
	$1/3 \times 10^{10}$	16/92	5.2×10^9
	$1/3 \times 10^{11}$	2/106	5.6×10^9
	$1/3 \times 10^{12}$	0/108	-


Claims

1. Method for selection of a specific ligand I which is expressed together with a phage coat protein on the surface of a phage, characterised by linking specific phage replication to recognition of said ligand I on the phage.
2. Method according to claim 1, characterised in that the linking of specific phage replication and recognition of ligand I on the phage surface is achieved by
 - a.) letting a helper phage stock, which phages do not have gene3 but carry protein3 on their coats, infect bacteria which comprises a phagemid vector with cloned ligand I;
 - b.) add a fusion protein between protein 3 or a part thereof, and a ligand II specifically interacting with said ligand I, so that ligand I and ligand II bind specifically to each other, and thereby also adding protein3 to those specific phages which carry ligand I;
 - c.) let said phages, which carry ligand I, ligand II and protein3 on their surface infect bacteria and thereby replicate and multiply.
3. Method according to claim 2, characterised by using a peptide, protein, antibody, antigen or fragment thereof as ligand I on the phage surface.
4. Method according to claim 2, characterised by using a peptide, protein or fragment thereof, organic molecule, hormone or other molecule as ligand II, which interacts specifically with ligand I, and is linked to protein3 in the fusion protein.
5. Method according to claim 1 or 2 characterised in using a human antibody or fragment thereof as ligand I on the phage surface.

Figure 1

B lymphocytes


PCR amplification

Phagemide cloning/
transfectionInfection by
M13 MDdelta3Ligand coupled
to protein 3*Clonal
selectionClonal
expansion

2/2

Figure 2

Effect of dp3-HEL fusion protein on specific infection



INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/01166

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 7/01, C12N 15/87, C12N 15/64, C07K 14/005, C07K 16/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, EMBASE, WPIL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	METHODS IN ENZYMOLOGY, Volume 217, 1993, G. P. Smith et al, "Libraries of Peptides and Proteins Displayed on Filamentous Phage" page 228 - page 257 --	1-5
A	WO, A1, 9301288 (DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS), 21 January 1993 (21.01.93), see claims --	1-5
A	NUCLEIC ACIDS RESEARCH, Volume 21, No 9, 1993, P. Waterhouse et al, "Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires" page 2265 - page 2266 --	1-5

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 March 1995

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Date of mailing of the international search report

17 -03- 1995

Authorized officer

Carl Olof Gustafsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/01166

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PROC. NATL. ACAD. SCI., Volume 87, April 1990, D. M. Kurnit et al, "Improved genetic selection for screening bacteriophage libraries by homologous recombination in vivo" page 3166 - page 3169 --	1-5
A	GENE, Volume 109, 1991, W. Markland et al, "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13" page 13 - page 19 --	1-5
P,X	BIO/TECHNOLOGY, Volume 12, October 1994, M. Duenas et al, "Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage Replication" page 999 - page 1002 -----	1-5

Information on patent family members

International application No.

PCT/SE 94/01166

Form PCT/ISA/210 (patent family annex) (July 1992)